Hedrington, Maka S <br/><br/>
Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes.  [electronic resource] 

 -  Expert opinion on biological therapy  03 2018 
 - 343-351 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1744-7682 
<br/><br/><label>Standard No.: </label>10.1080/14712598.2018.1439014  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Blood Glucose--analysis<br/>Body Weight<br/>Clinical Trials as Topic<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Glucagon-Like Peptide-1 Receptor--metabolism<br/>Glucagon-Like Peptides--chemistry<br/>Glycated Hemoglobin--analysis<br/>Humans<br/>Hypoglycemic Agents--chemistry<br/>Injections, Subcutaneous<br/>Glucagon-Like Peptide-1 Receptor Agonists